Asif Cochinwala
Expertise in
7
conditions

Dr. Asif Cochinwala

Rheumatology
1631 North Loop West, Ste 480, 
Houston, TX 
Accepting New Patients
Expertise in
7
conditions
1631 North Loop West, Ste 480, 
Houston, TX 

Overview

Asif Cochinwala is a Rheumatologist practicing medicine in Houston, Texas.

Dr. Cochinwala is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Rheumatoid Arthritis (RA), Undifferentiated Connective Tissue Disease (UCTD), Sjogren Syndrome, and Postmenopausal Osteoporosis.

He is actively involved in clinical research, participating in 7 clinical trials. Dr. Cochinwala is currently accepting new patients.

Specialties

Rheumatology

Licenses

Internal Medicine in TX

Fellowships

Baylor College of Medicine 1997

Hospital Affiliations

Memorial Hermann Greater Heights Hospital
Memorial Hermann Memorial City Hospital
Memorial Hermann Hospital System
Hca Houston Healthcare Kingwood

Languages Spoken

English
Hindi
Spanish
Urdu

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

1631 North Loop West, Ste 480, Houston, TX 77008
Other Locations
9614 Huffmeister Rd, Houston, TX 77095

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Vectra InVolved Informed Decision Outcome Study (VIVID): A Prospective Randomized Controlled Trial Evaluating the Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis
Vectra InVolved Informed Decision Outcome Study (VIVID): A Prospective Randomized Controlled Trial Evaluating the Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 21, 2026
Intervention Type: Diagnostic test
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Enrollment Status: Completed
Publish Date: March 27, 2024
Intervention Type: Biological, Drug
Study Drugs: GSK3196165, Tofacitinib, Methotrexate, Folic acid
Study Phase: Phase 3
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Olokizumab
Study Phase: Phase 3
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
Enrollment Status: Completed
Publish Date: July 17, 2023
Intervention Type: Drug, Biological
Study Drugs: GSK3196165, Sarilumab, csDMARDs
Study Phase: Phase 3
View 6 Less Clinical Trials
Similar Doctors
Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required
Before you request

Baylor Medicine Rheumatology

7200 Cambridge St, 
Houston, TX 
 (8.0 miles away)
713-798-3390
Languages Spoken:
English, Hindi, Punjabi
See accepted insurances
Accepting New Patients

Jasvinder Singh is a Rheumatologist practicing medicine in Houston, Texas. Dr. Singh is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Gout, Arthritis, Rheumatoid Arthritis (RA), Knee Replacement, and Hip Replacement. Dr. Singh is currently accepting new patients.

Expertise in
10
conditions
Expertise in
10
conditions
Referral may be required
Before you request
6410 Fannin St, Ste 450, 
Houston, TX 
 (7.0 miles away)
832-325-7191
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

John Reveille is a Rheumatologist practicing medicine in Houston, Texas. Dr. Reveille is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Ankylosing Spondylitis, Arthritis, Axial Spondyloarthritis (AxSpA), and Scleroderma. Dr. Reveille is currently accepting new patients.

Expertise in
8
conditions
Dr. Shervin Assassi
Rheumatology
Expertise in
8
conditions
Dr. Shervin Assassi
Rheumatology
Referral required
Before you request
6410 Fannin St, Ste 450, 
Houston, TX 
 (7.0 miles away)
713-486-3100
Languages Spoken:
English, Farsi
See accepted insurances
Accepting New Patients

Shervin Assassi is a Rheumatologist practicing medicine in Houston, Texas. Dr. Assassi is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Systemic Sclerosis (SSc), Scleroderma, Localized Scleroderma, and Pulmonary Fibrosis. Dr. Assassi is currently accepting new patients.

Frequently Asked Questions about Dr. Asif Cochinwala

How do I make an appointment with Dr. Asif Cochinwala?

You can book an appointment with Dr. Asif Cochinwala by calling their office at 832-237-0400. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Asif Cochinwala a top-rated expert for Rheumatoid Arthritis (RA)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Asif Cochinwala is classified as an Distinguished expert for Rheumatoid Arthritis (RA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Asif Cochinwala specialize in?

While Dr. Asif Cochinwala is a Rheumatology, they have specific expertise in Rheumatoid Arthritis (RA), Undifferentiated Connective Tissue Disease (UCTD), and Sjogren Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Rheumatology.

Does Dr. Asif Cochinwala accept my insurance?

Dr. Asif Cochinwala accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 832-237-0400 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cochinwala's expertise for a condition
ConditionClose
    View All 20 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile